Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration

BACKGROUND: We present the results of a Phase 2a randomized controlled trial investigating the safety, and secondary endpoints of subretinal rAAV.sFLT-1 gene therapy in patients with active wet age-related macular degeneration (wAMD). METHODS: All patients (n = 32), (ClinicalTrials.gov; NCT01494805)...

Descripción completa

Detalles Bibliográficos
Autores principales: Constable, Ian J., Pierce, Cora M., Lai, Chooi-May, Magno, Aaron L., Degli-Esposti, Mariapia A., French, Martyn A., McAllister, Ian L., Butler, Steve, Barone, Samuel B., Schwartz, Steven D., Blumenkranz, Mark S., Rakoczy, Elizabeth P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161436/
https://www.ncbi.nlm.nih.gov/pubmed/27865764
http://dx.doi.org/10.1016/j.ebiom.2016.11.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161436/
https://www.ncbi.nlm.nih.gov/pubmed/27865764
http://dx.doi.org/10.1016/j.ebiom.2016.11.016

Ejemplares similares